Fiche publication
Date publication
octobre 1991
Journal
Anti-cancer drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal
,
Pr MERLIN Jean-Louis
Tous les auteurs :
Merlin JL, Chastagner P, Marchal C, Weber B, Bey P
Lien Pubmed
Résumé
The aim of this in-vitro study was to evaluate the combination of busulfan with radiotherapy on TE-671 human medulloblastoma cells since unexpected clinical toxicity of busulfan was reported during the treatment of brain tumors, suggesting a possible radiopotentiation. The cytotoxicity of busulfan was determined by using colony forming assays, and doses inducing growth inhibitions of 10, 20 and 50% were selected to be tested in association: 6, 12 and 32 mumol/l for busulfan and 0.5, 1 and 3 Gy for irradiation. All possible combinations were considered within this frame and the results showed that the combination of busulfan with radiotherapy exerted an additive effect without potentiation.
Mots clés
Busulfan, administration & dosage, Cell Line, Cerebellar Neoplasms, pathology, Colony-Forming Units Assay, Combined Modality Therapy, Humans, Medulloblastoma, pathology, Tumor Cells, Cultured, drug effects
Référence
Anticancer Drugs. 1991 Oct;2(5):465-8
